Impact of a nursing intervention on frailty in people aged 65-75 years in primary care. A pilot clinical trial.

Enferm Clin (Engl Ed)Jul 20, 2026 (epub)
Case ReportGeriatricsFamily Medicine

Yolanda Rodríguez-Vieira, Vanesa Rojo-Amigo, Carmen Neri Fernández-Pombo

✦ AI-curated · Sources linked

Condensed from the publisher's abstract. An xxcode editorial summary of this publication has not been generated yet.

From the abstract

To analyse whether an intervention carried out by primary care nurses modifies the degree of frailty in people between 65 and 75 years of age.

Reported results

The final sample was 11 patients for the CG and 10 patients for the IG. The IG had significantly lower frailty at the end of follow-up compared to the CG (non-frail IG 80% vs. non-frail CG 18.1%, P=.0041). There were no differences in biomedical measurements, anthropometric data and in the questionnaires applied, however, the IG presented full compliance with physical exercise recommendations compared to the CG (100…

Authors' conclusions

The nursing intervention for the management of frailty carried out in the IG reduces the number of patients with frailty.

Source

PubMed · PMID 42476315

Published in Enferm Clin (Engl Ed). The text above is extracted from the publisher's own abstract and has not been edited by xxcode. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.